PMID: 9641502Jun 26, 1998Paper

A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids

Clinical Rheumatology
R OlinP A Berg

Abstract

The aim of the study was to evaluate in a double-blind manner the effect of the long-acting 5-hydroxytryptamine 2 (5-HT2)-receptor blocker Ritanserin on clinical symptoms in patients with fibromyalgia syndrome (FM) and on production of antibodies to serotonin, gangliosides and phospholipids, recently shown to have a high incidence in this disease. Fifty-one female patients with typical FM were included in the 16-week study: 24 received Ritanserin and 27 received a placebo. Antibodies to 5-HT, gangliosides (Gm1) and phospholipids (thromboplastin) were determined by enzyme-linked immunosorbent assay at day 0 and at the end of week 16. The psychological and physical status, including tender points, of the patients was evaluated at day 0 and at the end of weeks 4 and 16. At the end of the study, there was an improvement (p < 0.05) in feeling refreshed in the morning in the Ritanserin-treated group and headache was also significantly improved compared with the placebo group. There was no difference in pain, fatigue, sleep, morning stiffness, anxiety and tender point counts in the Ritanserin and placebo groups. Fifty-one per cent of the 51 patients had at least one of the three antibodies to 5-HT, Gm1 and phospholipids. The incidence...Continue Reading

References

Jun 1, 1992·Headache·B J AnsinkJ G Smakman
May 10, 1985·Journal of Immunological Methods·R UrbanekD Samuel
Mar 25, 1994·Deutsche medizinische Wochenschrift·P A Berg, R Klein

❮ Previous
Next ❯

Citations

May 7, 2008·Der Schmerz·C SommerD O Nutzinger
Jul 5, 2012·Der Schmerz·C SommerUNKNOWN Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
May 1, 2008·Rheumatology·S PerrotUNKNOWN CEDR (Cercle d'Etude de la Douleur en Rhumatologie France), French Rheumatological Society, Pain Study Section
Oct 13, 2000·Journal of General Internal Medicine·P G O'MalleyJ L Jackson
Jul 22, 2008·Rheumatic Diseases Clinics of North America·Serge PerrotFrançoise Laroche
Feb 24, 2006·European Journal of Pain : EJP·Serge PerrotRichard Trèves
Nov 24, 1999·Baillière's Best Practice & Research. Clinical Rheumatology·D Buskila
Aug 1, 2003·Acta Neuropsychiatrica·Harald Murck
May 13, 1999·Current Opinion in Rheumatology·D Buskila
Nov 27, 2019·International Journal of Molecular Sciences·Gianluca Baldanzi, Mario Malerba

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

© 2022 Meta ULC. All rights reserved